Publications.
Exit strategies in patients with stable MS: Cost-effectiveness of extended interval dosing of ocrelizumab and natalizumab versus de-escalating to cladribine
Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model
Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model
Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model
Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis
The potential impact of digial biomarkers in multiple slerosis in the Netherlands: an early HTA technology assessment of MS Sherpa
Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis
Summarizing patient preferences for the competitive landscape of multiple sclerosis treatment options
